TISIDB

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted Golgi apparatus
Domain	PF12260 Protein-kinase domain of FAM69
Function	Secreted tyrosine-protein kinase that mediates phosphorylation of extracellular proteins and endogenous proteins in the secretory pathway, which is essential for patterning at organogenesis stages. Mediates phosphorylation of MMP1, MMP13, MMP14, MMP19 and ERP29 (PubMed:25171405). Probably plays a role in platelets: rapidly and quantitatively secreted from platelets in response to stimulation of platelet degranulation (PubMed:25171405). May also have serine/threonine protein kinase activity. Required for longitudinal bone growth through regulation of chondrocyte differentiation. May be indirectly involved in protein transport from the Golgi apparatus to the plasma membrane (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001503 ossification GO:0002062 chondrocyte differentiation GO:0007009 plasma membrane organization GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0030278 regulation of ossification GO:0030282 bone mineralization GO:0030323 respiratory tube development GO:0030324 lung development GO:0030500 regulation of bone mineralization GO:0030501 positive regulation of bone mineralization GO:0031214 biomineral tissue development GO:0032330 regulation of chondrocyte differentiation GO:0032332 positive regulation of chondrocyte differentiation GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035264 multicellular organism growth GO:0042996 regulation of Golgi to plasma membrane protein transport GO:0042997 negative regulation of Golgi to plasma membrane protein transport GO:0043001 Golgi to plasma membrane protein transport GO:0045778 positive regulation of ossification GO:0048286 lung alveolus development GO:0048565 digestive tract development GO:0048566 embryonic digestive tract development GO:0048568 embryonic organ development GO:0048736 appendage development GO:0051051 negative regulation of transport GO:0051216 cartilage development GO:0051224 negative regulation of protein transport GO:0055123 digestive system development GO:0060021 palate development GO:0060173 limb development GO:0060541 respiratory system development GO:0061035 regulation of cartilage development GO:0061036 positive regulation of cartilage development GO:0061448 connective tissue development GO:0070167 regulation of biomineral tissue development GO:0070169 positive regulation of biomineral tissue development GO:0072657 protein localization to membrane GO:0072659 protein localization to plasma membrane GO:0090002 establishment of protein localization to plasma membrane GO:0090003 regulation of establishment of protein localization to plasma membrane GO:0090005 negative regulation of establishment of protein localization to plasma membrane GO:0090150 establishment of protein localization to membrane GO:1903076 regulation of protein localization to plasma membrane GO:1903077 negative regulation of protein localization to plasma membrane GO:1903729 regulation of plasma membrane organization GO:1903828 negative regulation of cellular protein localization GO:1904375 regulation of protein localization to cell periphery GO:1904376 negative regulation of protein localization to cell periphery GO:1904950 negative regulation of establishment of protein localization GO:1990778 protein localization to cell periphery
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004715 non-membrane spanning protein tyrosine kinase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PKDCC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PKDCC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PKDCC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.324	0.00177
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.81	0.109
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.973	0.296
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.092	0.15
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.561	0.773
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.76	0.473
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.249	0.602
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.633	0.564
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.139	0.906
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.037	0.983
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.15	0.618
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.598	0.0188

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PKDCC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	4.1	-4.1	0.561
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PKDCC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PKDCC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PKDCC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PKDCC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PKDCC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PKDCC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PKDCC
Name	protein kinase domain containing, cytoplasmic
Aliases	SgK493; Vlk; vertebrate lonesome kinase; protein kinase domain containing, cytoplasmic homolog (mouse); prot ......
Chromosomal Location	2p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PKDCC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PKDCC